{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-000435","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2026-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.870644+00:00","generated_at":"2026-05-16T11:28:47.781995+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Bepirovirsen Phase 3 positive: primary endpoint met, functional cure rates superior to SOC","bullets":["Over 1,800 patients enrolled in two Phase 3 studies (B-Well 1 & 2) across 29 countries.","Bepirovirsen + SOC achieved statistically significant functional cure rates vs. SOC alone on all ranked endpoints.","Ionis eligible for up to $150M in regulatory/sales milestones plus 10-12% tiered royalties.","Global regulatory submissions planned from Q1 2026; potential first finite 6-month CHB therapy.","Drug has Fast Track FDA, Breakthrough Therapy China, and SENKU Japan designations."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-000435","json":"https://secwatch.observer/filing/0001140361-26-000435.json","markdown":"https://secwatch.observer/filing/0001140361-26-000435.md","text":"https://secwatch.observer/filing/0001140361-26-000435.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036126000435/0001140361-26-000435-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036126000435/ef20062477_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:28:47.781995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}